Vision by 2030

Responsibly lead the transition of adult smokers to a smoke-free future. 

Moving Beyond Smoking

Our industry stands at a pivotal moment. Today, approximately 22 million U.S. adult smokers are interested in less harmful tobacco products. That’s why we’re leveraging the resources across our companies, and through strategic investments, to offer the most diverse portfolio of products to satisfy adult preferences and transition adult smokers to smoke-free products.

Our team of more than 250 scientists, physicians, product developers, engineers and regulatory experts from around the world share a common goal – advancing tobacco harm reduction. To that end, we invest in the foundational science needed to demonstrate that smoke-free tobacco products are less harmful than cigarettes and to support the product applications we submit to the U.S. Food and Drug Administration (FDA).

Together, we are dedicated to researching innovative products, pursuing regulatory authorization by FDA and constructively engaging with regulatory bodies, the broader scientific community and other stakeholders.  Much of this work occurs at our Center for Research & Technology in Richmond, Virginia. 

Maria Gogova

Global Tobacco & Nicotine Forum's virtual "THR in Focus"

On April 27th, Dr. Maria Gogova presented at the Global Tobacco & Nicotine Forum’s virtual "THR in Focus" program.

Altria Scientists at the 27th Society for Research on Nicotine and Tobacco (SRNT) Virtual Conference – February 24-27, 2021

On an annual basis SRNT offers an opportunity for diverse stakeholders to come together to share tobacco product research. This year our scientists participated in the 27th SRNT virtual conference showcasing 16 posters.